实用临床医药杂志2012，Vol.16Issue(23)：100-101,103,3.
多西他赛联合卡培他滨在晚期非小细胞肺癌二线化疗中的疗效及安全性观察
Efficacy and safety of docetaxel plus capecitabine as second-line treatment in treating patients with advanced non-small cell lung cancer
摘要
Abstract
Objective To observe efficacy and safety of docetaxel plus capecitabine as second -line treatment in treating patients with advanced non-small cell lung cancer (NSCLC). Methods 26 patients who failed in platinum - based first-line chemotherapy with good performance status (scoring 0-1) were treated with docetaxel plus capecitabine. The objective curative effect, survival time and adverse reactions were evaluated. Results Among the 26 patients, there were 5 cases of PR, 10 cases of SD, 11 cases of PD. The median progression-free survival time was 5.2 months, the median overall survival time was 9. 6 months, and the 1-year survival rate was 26. 92% . 5 cases had grade HI ~IV neutropenia, only 1 case had grade HI hand-foot syndrome. Conclusion Combination of docetaxel and capecitabine as second-line treatment is an effective chemotherapy regimen for patients with advanced noirsmall cell lung cancer,and its side effects also can be tolerated.关键词
非小细胞肺癌/二线化疗/多西他赛/卡培他滨Key words
advanced non-small cell lung cancer/second-line treatment/docetaxel/capecitabine分类
医药卫生引用本文复制引用
周建红,李桂生,李高峰,黄健..多西他赛联合卡培他滨在晚期非小细胞肺癌二线化疗中的疗效及安全性观察[J].实用临床医药杂志,2012,16(23):100-101,103,3.基金项目
中国高校医学期刊临床专项资金(11220242) （11220242）
